Nature's Sunshine Products: Profit Decline, But Still Undervalued


  • Nature's Sunshine Products has performed well over 2021 compared to 2020, with improvements across the board.
  • But cost increases in 2022 from inflation and currency translations have led to a profit decline.
  • Despite this, the company is undervalued compared to peers, with a potential upside of around 30-50%.

Overhead view of senior Asian woman feeling sick, taking medicines in hand with a glass of water at home. Elderly and healthcare concept



Nature's Sunshine Products, Inc. (NASDAQ:NATR) performed well in 2021, but 2022 profits are suffering due to increased costs of inputs. Despite this, the stock is undervalued compared to peers, with a potential upside of around 30-50%, but very much comes with a

Revenue split


Share price

Yahoo Finance

Stock performance


Sales chart


Costs chart



SEC, Yahoo Finance


SEC, Yahoo Finance

This article was written by

Focus on value and special situations. Anything I write is simply my personal opinion and should not be taken as trading advice.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.